TapImmune, Inc. (OTCQB: TPIV) is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). SNNLive spoke with Dr. Glynn Wilson, Chairman and CEO of TapImmune, Inc. at the Healthcare Media Day 2015 in San Francisco, CA.
Dr. Wilson begins with an overview of the company, “TapImmune is a very exciting company specializing in immunotherapy, which is really stimulating the body’s own immune system to recognize and kill cancer cells and it can also be used for the treatment of infectious disease.” He continues with what approach the company’s treatment takes, “The approach we take is to stimulate in a very comprehensive way T-cells, both T-helper cells and T-killer cells and we also have approaches to enhance what is called antigen presentation, which means that the immune system can see more signal on the surface of aberrant cells to recognize and kill them. We think we have the most comprehensive approach in development.”
He then goes into what personalized medicine is and how TapImmune incorporates that concept into their treatment strategy, “We do have a personalized strategy in a sense that we target our therapies to individual genetics of the immune system. Every one of us has different genetics, that’s what leads to things like transplantation rejection, so we have the ability to develop vaccines that can target specific subsets of people’s genetics. So in other words, we can put a comprehensive platform together. Our HER2/neu vaccine can treat approximately about 85% of the population.”
He concludes with what to look forward in the next year, “The key thing for us in 2015 is to get the two clinical trials that we have, one in HER2/neu breast cancer, one in ovarian and triple negative breast cancer advanced into Phase 2 and we’re doing matters as rapidly and as efficiently as we can. In addition to that, we’re also planning to advance our in-house developed technologies such as PolyStart and possible TAP to be key components of a future vaccine. So it’s a combination of those two things and there are a lot of exciting things on the horizon in addition to, you know the overall financing of the company.” For more information, check out their website: www.TapImmune.com
© 2017 Stock News Now
Supported by Superior Web Solutions